经皮穿刺肝动脉化疗栓塞在肝细胞肝癌根治性切除术后的应用
被引量：2
摘要
肝细胞肝癌（肝癌）是肝脏最常见的恶性肿瘤。手术切除是治疗肝癌的首选方法。早期肝癌患者根治性肝切除术后5年生存率可达到50％～70％。
出处
《中华肝脏外科手术学电子杂志》
CAS
2013年第5期5-8,共4页
Chinese Journal of Hepatic Surgery(Electronic Edition)
参考文献6
-
1徐峰,黄杨卿,伍路,杨甲梅.肝细胞癌根治性切除术后辅助性经导管肝动脉化疗栓塞价值的前瞻性研究[J].第二军医大学学报,2012,33(4):390-394. 被引量：5
-
2蔡建强,李聪,毕新宇.肝癌复发转移的防治策略[J].外科理论与实践,2012,17(5):427-429. 被引量：4
-
3陈晓泓,张博恒,殷欣,邱双健,樊嘉,任正刚,夏景林,王艳红,叶胜龙,干育红.肝细胞癌根治术后行辅助性肝动脉化疗栓塞对近期复发的作用[J].中华医学杂志,2010,90(12):826-829. 被引量：20
-
4李锦清,张亚奇,张伟章,元云飞陈敏山,郭荣平,林小军,李国辉.栓塞化疗在肝癌切除术后的价值[J].中华肿瘤杂志,1994,16(5):387-389. 被引量：51
-
5Zheng-GangRen Zhi-YingLin Jing-LinXia Sheng-LongYe Zeng-ChenMa Qing-HaiYe Lun-XiuQin Zhi-QuanWu JiaFan Zhao-YouTang.Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor:A retrospective control study[J].World Journal of Gastroenterology,2004,10(19):2791-2794. 被引量：83
-
6陆进,王卫东,徐平,范晨.肝动脉化疗栓塞对肝癌术后高危复发患者的疗效分析[J].现代消化及介入诊疗,2011,16(4):239-241. 被引量：6
二级参考文献24
-
1Wan-Yee Lau,Eric C.H.Lai,Stephanie H.Y.Lau.The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma:a systematic review[J].Hepatobiliary & Pancreatic Diseases International,2009,8(2):124-133. 被引量：24
-
2刘鹏飞,刘荣华,徐荷,吴孟超.原发性肝癌术后预防性TACE的意义(附433例病例随访)[J].中华肝胆外科杂志,2005,11(2):81-82. 被引量：52
-
3程红岩,徐雯,徐爱民,陈栋,杨业发,贾雨辰.肝动脉插管化疗栓塞在预防肝癌术后复发中的应用价值[J].中华肿瘤杂志,2005,27(10):626-628. 被引量：30
-
4奚韬,闫振林,王葵,李俊,夏勇,沈锋,吴孟超.术后经导管动脉化疗栓塞对不同病理特征肝癌的抗复发作用[J].中华外科杂志,2007,45(9):587-590. 被引量：23
-
5李国辉，J Surg Oncol，1989年，42卷，181页
-
6Tang Z Y，Subclinical Hepatocellular Carcinoma，1985年，1卷
-
7Jemal A, Bray F, Center MM, et al. Global cancer statis- tics[J]. Ca Cancer J Clin,2011,61(2):69-90.
-
8Shah SA, Greig PD, Gallinger S, et al. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes[J]. J Am Coll Surg,2006,202(2): 275-283.
-
9Zhou WP, Lai EC, Li AJ, et al. A prospective, rando- mized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma[J]. Ann Surg,2009,249(2):195-202.
-
10E1-Serag HB. Epidemiology of hepatocellular carcinomain USA[J]. Hepatol Res,2007,37 (suppl 2) :s88-s94.
共引文献158
-
1Tianfu Wen,Chen Jin,Antonio Facciorusso,Matteo Donadon,Ho-Seong Han,Yilei Mao,Chaoliu Dai,Shuqun Cheng,Bixiang Zhang,Baogang Peng,Shunda Du,Changjun Jia,Feng Xu,Jie Shi,Juxian Sun,Peng Zhu,Satoshi Nara,JMichael Millis,Qiu Li,Weixia Chen,Wusheng Lu,Hong Tang,Lvnan Yan,Yong Zeng,Bo Li,Jiayin Yang,Wentao Wang,Hong Wu,Mingqing Xu,Zheyu Chen,Changli Lu,Chuan Li,Wei Peng,Xiaoyun Zhang.Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus[J].Hepatobiliary Surgery and Nutrition,2018,7(5):353-371. 被引量：42
-
2周庆湘.肝癌患者区域性化疗2种注射方法不良反应的观察[J].当代护士（中旬刊）,2006,13(7):63-64.
-
3Wan-Yee Lau,Eric C.H.Lai,Stephanie H.Y.Lau.The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma:a systematic review[J].Hepatobiliary & Pancreatic Diseases International,2009,8(2):124-133. 被引量：24
-
4Wan-Ping Chen, Xin He, Qi-Fa Ye and Ke Li Institute of Organ Transplantation, Third Xiangya Hospital, Xiangya Medical College, Central South University, Changsha 410013, China, and Institute of Clinical Pharmacology, Xiangya Medical College, Central South University, Changsha 410078, China.Implantation of a drug delivery system during surgery for patients with primary hepatocarcinoma[J].Hepatobiliary & Pancreatic Diseases International,2006,5(3):391-395. 被引量：2
-
5华赟鹏,彭宝岗.预防原发性肝癌术后复发的策略研究[J].消化肿瘤杂志（电子版）,2011,3(2):70-73. 被引量：3
-
6元云飞,李斌奎,李锦清,张亚奇,郭荣平,林小军,李国辉.巨大肝癌手术切除治疗的远期疗效[J].癌症,2004,23(7):821-824. 被引量：19
-
7刘平果,王效民,李永国,尹震宇,吴国洋,于仁祥.巨大原发性肝癌并门静脉癌栓的肝切术联合取癌栓的疗效分析[J].中华肝胆外科杂志,2004,10(1):64-64. 被引量：2
-
8黎洪浩,王捷,段朝晖,张红卫,陈积圣.干扰素联合肝动脉化疗栓塞和门静脉化疗对预防肝癌切除术后复发的价值[J].中华肿瘤杂志,2004,26(9):558-561. 被引量：12
-
9张国生,李小明,王向.肝动脉栓塞化疗(TACE)对肝癌切除术后复发的影响[J].赣南医学院学报,2004,24(6):718-719. 被引量：2
-
10黄栋,赫军,罗建强,梁中骁,黄宇.肝癌切除术中肝动脉、门静脉留置IDDS对术后复发的防治价值[J].医学文选,2005,24(1):8-10. 被引量：2
同被引文献20
-
1Matan J Cohen,Allan I Bloom,Orly Barak,Alexander Klimov,Tova Nesher,Daniel Shouval,Izhar Levi,Oren Shibolet.Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma[J].World Journal of Gastroenterology,2013,19(16):2521-2528. 被引量：13
-
2Tan To Cheung,Sheung Tat Fan,See Ching Chan,Kenneth SH Chok,Ferdinand SK Chu,Caroline R Jenkins,Regina CL Lo,James YY Fung,Albert CY Chan,William W Sharr,Simon HY Tsang,Wing Chiu Dai,Ronnie TP Poon,Chung Mau Lo.High-intensity focused ultrasound ablation:An effective bridging therapy for hepatocellular carcinoma patients[J].World Journal of Gastroenterology,2013,19(20):3083-3089. 被引量：23
-
3Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
-
4Meza-Junco J, Montano-Loza A J, Liu DM, et al. Locoregional radiological treatment for hepatocellular carcinoma: which, when and how?[J]. Cancer Treat Rev, 2012, 38(1): 54-62.
-
5Giammarile F, Bodei L, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra- arterial radioactive compounds[J]. Eur J Nucl Med Mol Imaging, 2011, 38(7): 1393-1406.
-
6Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres[J]. Hepatology, 2009, 49(4): 1185-1193.
-
7Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization[J]. Am J Transplant,2009, 9(8): 1920-1928.
-
8Kooby DA, Egnatashvili V, Srinivasan S, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2010, 21 (2): 224-230.
-
9Lance C, Mclennan G, Obuchowski N, et al. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2011, 22(12): 1697-1705.
-
10Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma[J]. Gastroenterology, 2011, 140(2): 497-507.
引证文献2
-
1胡昆鹏,汤照峰,姚志成,林继宗,黄品助,邓美海,许瑞云,刘波.肝细胞癌经导管动脉化疗栓塞术后严重并发症患者的诊治体会[J].中华肝脏外科手术学电子杂志,2014,3(2):36-39. 被引量：1
-
2李慕行,张谞丰,程继文,朱迎,王万里,董健,龙志达,吕毅.钇-90微球经动脉放疗栓塞治疗不可切除原发性肝癌疗效的Meta分析[J].中华肝脏外科手术学电子杂志,2014,3(6):20-23. 被引量：4
二级引证文献5
-
1侯帅,樊琳琳,戴光荣.非手术治疗原发性肝癌研究进展[J].实用肝脏病杂志,2016,19(2):249-252. 被引量：40
-
2杨志艳,刘军山,张秀文.肝癌介入治疗后并发胆汁瘤CT表现及临床意义[J].检验医学与临床,2017,14(15):2199-2200. 被引量：2
-
3李红,尹芳,罗贯虹,武建,郑洋洋,曹国武,张静,周新民.CalliSpheres载药脂微球联合TACE与传统TACE治疗肝癌疗效对比分析[J].胃肠病学和肝病学杂志,2019,28(2):171-174. 被引量：17
-
4马婧嶔,颜志平.肝癌介入治疗进一步思考[J].介入放射学杂志,2019,28(6):507-510. 被引量：20
-
5王志鹏,尹晶晶,许文黎,孙鸽,高洁,张伟,秦秀军,李建国,刘欢.VX2兔肝癌原位模型与肝动脉介入放射性栓塞微球方法的建立及辐射防护策略[J].辐射防护通讯,2021,41(5):6-9.
-
1樊嘉,吴志全,汤钊猷,马曾辰,周信达,周俭,邱双健,钦伦秀,叶青海.不能切除肝癌缩小后二期切除疗效及影响预后因素[J].中华肝胆外科杂志,2001,7(11):649-653. 被引量：6
-
2樊嘉,余业勤,吴志全,汤钊猷,马曾辰,周信达,周俭,陆继珍.肝细胞癌经皮穿刺肝动脉化疗栓塞缩小后切除及疗效分析[J].中华外科杂志,1997,35(12):710-712. 被引量：9
-
3沈伟峰,杨甲梅.特殊类型的肝胆管细胞肝癌一例诊治体会[J].中华肝脏外科手术学电子杂志,2013,2(5):59-59.
-
4杨子明.肝细胞癌经皮穿刺肝动脉化疗栓塞缩小后切除及疗效分析[J].中华医学信息导报,1998,0(2):15-16.
-
5丁淑容,彭艳.不同区域化疗对肝癌复发的影响[J].中国医学工程,2009,17(5):372-374.
-
6张全保,陶一峰,李瑞东,邹丽萍,马震宇,张晓飞,王正昕.原位肝移植治疗肝脏上皮样血管内皮瘤(附2例报告及文献复习)[J].器官移植,2017,8(1):59-65. 被引量：9
-
7李新丰,吕国荣,王高雄,刘德鑫,李拾林.TACE联合RF和TACE治疗中晚期肝癌的临床观察[J].中华肝胆外科杂志,2003,9(1):23-25. 被引量：17
-
8黄泽坚,商昌珍,张培东,郑哲宇,张磊.经皮穿刺肝动脉化疗栓塞联合经皮及腹腔镜下微波固化治疗大肝细胞肝癌[J].中华肝脏外科手术学电子杂志,2013,2(6):36-38. 被引量：2
-
9向国安,陈开运,王汉宁,肖方联,肖金丰,余智涛.介入治疗在提高中晚期肝癌二期切除率中的疗效及意义[J].中国基层医药,2007,14(2):264-266. 被引量：2
-
10李新丰,刘保军,吕国荣,王高雄,刘德鑫.TACE联合RFA治疗原发性肝癌的临床研究[J].中华腹部疾病杂志,2002,2(4):302-303.
